China Nuokang Bio-Pharmaceutical Inc. [NASDAQ: NKBP] has announced that the company plans to release third quarter 2012 financial results on Sunday, November 25, 2012.
Nuokang is a leading biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hospital-based medical products. Nuokang’s principal products include Baquting®, China’s leading hemocoagulase product by market share; Kaitong®, a lipid emulsion alprostadil product for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders, and post-surgery thrombosis; and alpha lipoic acid (ALA) capsules, an antioxidant product that addresses diabetic neuropathy.
The Company’s product pipeline includes product candidates under development in hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. Nuokang has five patents currently pending: a compositus hemostatic; a pharmacodynamical experiment method of adenosine drug; a preparation method of thymosin from sheep; a directed mutation genetic engineering Batroxobin and its application; and an emulsion for fluids for infusion which contains alprostadil and its preparation method.
Nuokang’s end-customer base includes approximately 80% of the Class 3A hospitals in major Chinese cities, and the Company receives strong academic support from a specialist network comprising approximately 100 national key opinion leaders and physicians in various clinical areas.